DaVita Inc. (DVA) has a MoatMap StockRank of 100/100 based on Quality (62/100), Value (64/100), and Momentum (82/100) factor scores. The current signal is STRONG BUY. DaVita provides essential dialysis services, but it lacks a clear, powerful macro tailwind or asymmetric opportunity that the market has not priced, failing to meet the Druckenmiller lens requirements. Its business model, while stable, is not a high-growth compounder in the context of the fund's philosophy.
DaVita Inc. is a leading global provider of kidney dialysis services, operating an extensive network of outpatient dialysis centers across the United States and internationally. The company benefits from its significant scale, robust clinical outcomes, and integrated care model designed to improve patient health and quality of life. DaVita's competitive moat is reinforced by its strong brand recognition, established relationships within the healthcare system, and a deeply embedded role in managing chronic kidney disease.
| Price | $198.52 |
| Market Cap | $12.7B |
| P/E (TTM) | 18.77 |
| P/E (Forward) | 11.33 |
| Price/Book | -17.05 |
| Return on Equity | 81.0% |
| Return on Invested Capital | 13.4% |
| Debt/Equity | 1261.33 |
| Gross Margin | 32.5% |
| Operating Margin | 13.9% |
| Revenue Growth | 6.0% |
| Free Cash Flow | $1000M |
DaVita Inc. operates in the Medical Care Facilities industry, part of the Healthcare sector (United States).